Castet Valérie, Fournier Chantal, Soulier Alexandre, Brillet Rozenn, Coste Joliette, Larrey Dominique, Dhumeaux Daniel, Maurel Patrick, Pawlotsky Jean-Michel
INSERM U128, Montpellier, France.
J Virol. 2002 Aug;76(16):8189-99. doi: 10.1128/jvi.76.16.8189-8199.2002.
Chronic hepatitis C is a common cause of liver disease, the complications of which include cirrhosis and hepatocellular carcinoma. Treatment of chronic hepatitis C is based on the use of alpha interferon (IFN-alpha). Recently, indirect evidence based on mathematical modeling of hepatitis C virus (HCV) dynamics during human IFN-alpha therapy suggested that the major initial effect of IFN-alpha is to block HCV virion production or release. Here, we used primary cultures of healthy, uninfected human hepatocytes to show that: (i) healthy human hepatocytes can be infected in vitro and support HCV genome replication, (ii) hepatocyte treatment with IFN-alpha results in expression of IFN-alpha-induced genes, and (iii) IFN-alpha inhibits HCV replication in infected human hepatocytes. These results show that IFN-alpha acts primarily through its nonspecific antiviral effects and suggest that primary cultures of human hepatocytes may provide a good model to study intrinsic HCV resistance to IFN-alpha.
慢性丙型肝炎是肝脏疾病的常见病因,其并发症包括肝硬化和肝细胞癌。慢性丙型肝炎的治疗基于使用α干扰素(IFN-α)。最近,基于人类IFN-α治疗期间丙型肝炎病毒(HCV)动力学的数学模型得出的间接证据表明,IFN-α的主要初始作用是阻断HCV病毒粒子的产生或释放。在此,我们使用健康、未感染的人肝细胞原代培养物来证明:(i)健康人肝细胞可在体外被感染并支持HCV基因组复制,(ii)用IFN-α处理肝细胞会导致IFN-α诱导基因的表达,以及(iii)IFN-α抑制感染的人肝细胞中的HCV复制。这些结果表明,IFN-α主要通过其非特异性抗病毒作用发挥作用,并提示人肝细胞原代培养物可能为研究HCV对IFN-α的内在抗性提供一个良好的模型。